AR018191A1 - Uso de glucocorticosteroides para la manufactura de un medicamento para tratar enfermedades pulmonares obstructivas cronicas - Google Patents

Uso de glucocorticosteroides para la manufactura de un medicamento para tratar enfermedades pulmonares obstructivas cronicas

Info

Publication number
AR018191A1
AR018191A1 ARP990101816A ARP990101816A AR018191A1 AR 018191 A1 AR018191 A1 AR 018191A1 AR P990101816 A ARP990101816 A AR P990101816A AR P990101816 A ARP990101816 A AR P990101816A AR 018191 A1 AR018191 A1 AR 018191A1
Authority
AR
Argentina
Prior art keywords
manufacture
obstructive pulmonary
copd
chronic obstructive
pulmonary diseases
Prior art date
Application number
ARP990101816A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR018191A1 publication Critical patent/AR018191A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de glucocorticosteroide para la manufactura de un medicamento para tratar enfermedades pulmonares cronicas obstructivas (COPD) en pacientes que tienenun valor de volumen de expiracion forzada en 1 segundo (FEV1.0) > 65% del valor pronosticado y <10% de reversibilidad en ensayos de broncodilatacion. Laenfermedad pulmonar obstructiva cronica (COPD) es un enfermedad comun en los países industrializados (aproximadamente 6% de los hombres y 4% de las mujeres demás de 45 anos en el reino Unido están afectados) y es responsable de una considerable morbilidad y mortalidad. La mayoría de los pacientes son fumadores. Losdos trastornos más importantes que están asociados con COPD son la bronquitis cronica y la enfísema. Se proveen compuestos apropiados para la manufactura de unmedicamento para el tratamiento de COPD livianas/precoces, incluyendo la atenuacion de la declinacion de la funcion pulmonar.
ARP990101816A 1998-04-20 1999-04-20 Uso de glucocorticosteroides para la manufactura de un medicamento para tratar enfermedades pulmonares obstructivas cronicas AR018191A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801368A SE9801368D0 (sv) 1998-04-20 1998-04-20 New use

Publications (1)

Publication Number Publication Date
AR018191A1 true AR018191A1 (es) 2001-10-31

Family

ID=20411015

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101816A AR018191A1 (es) 1998-04-20 1999-04-20 Uso de glucocorticosteroides para la manufactura de un medicamento para tratar enfermedades pulmonares obstructivas cronicas

Country Status (10)

Country Link
EP (1) EP1073441A1 (es)
JP (1) JP2002512193A (es)
CN (1) CN1306429A (es)
AR (1) AR018191A1 (es)
AU (1) AU3062599A (es)
BR (1) BR9909786A (es)
CA (1) CA2329008A1 (es)
HK (1) HK1038703A1 (es)
SE (1) SE9801368D0 (es)
WO (1) WO1999053926A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912534D0 (en) 1999-05-29 1999-07-28 Glaxo Group Res Ltd Novel prognostic surrogate
ECSP003747A (es) * 1999-11-02 2002-05-23 Smithkline Beecham Corp Metodo y composiciones para el tratamiento de las enfermedades pulmonares
DK1572217T3 (da) 2002-12-12 2008-12-15 Nycomed Gmbh Kombinationsmedikament af R,R-formoterol og ciclesonid
WO2004070058A1 (en) * 2003-02-03 2004-08-19 Bayer Healthcare Ag Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of copd
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
ES2452691T5 (es) 2003-09-16 2022-09-14 Covis Pharma Gmbh Uso de ciclesonida para el tratamiento de enfermedades respiratorias
CA2540005A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Pulmonary disease treatment
JP2007533706A (ja) * 2004-04-20 2007-11-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用

Also Published As

Publication number Publication date
HK1038703A1 (zh) 2002-03-28
AU3062599A (en) 1999-11-08
CN1306429A (zh) 2001-08-01
CA2329008A1 (en) 1999-10-28
BR9909786A (pt) 2000-12-19
WO1999053926A1 (en) 1999-10-28
JP2002512193A (ja) 2002-04-23
EP1073441A1 (en) 2001-02-07
SE9801368D0 (sv) 1998-04-20

Similar Documents

Publication Publication Date Title
Pavithra Eugenol-a review
Kaiser et al. Systemic hypotension: a risk factor for glaucomatous damage?
AR018191A1 (es) Uso de glucocorticosteroides para la manufactura de un medicamento para tratar enfermedades pulmonares obstructivas cronicas
ES2093735T3 (es) Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
YU106192A (sh) Nova kombinacija bronhodilatatora i steroidnog antiinflamatornog leka za lečenje respiratornih poremećaja
Capasso et al. Reduction of agonist‐induced contractions of guinea‐pig isolated ileum by flavonoids
AR018717A1 (es) COMPUESTOS DERIVADOS DE PIPERIDINA, SU USO, UN PROCESO PARA SU PREPARACIoN, COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN, Y COMPUESTOS INTERMEDIARIOS.
CR6834A (es) Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo
ES2153906T3 (es) Uso de incienso para el tratamiento de la enfermedad de alzheimer.
Verma et al. Evaluation of analgesic activity of Syzygium aromaticum w. sr to painful tooth
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
BRPI0409935A (pt) composição para aperfeiçoar percepção e memória
US6440391B1 (en) Management of snoring by oral administration of dimethyl sulfone
CO4940448A1 (es) Modificacion a cristal de una sustancia de medicamento
Grover et al. Curcumin: A medicinal plant and its effects in medicine and dentistry
EA200001049A1 (ru) Новые способы лечения нервных расстройств
BR9802153A (pt) Método de obtenção e uso do extrato da rosmarinus officinalis,no tratamento de várias doenças.
Perić et al. Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray
ES2086536T3 (es) Uso de ketorolaco para el tratamiento de la enfermedad periodontal.
AR042152A1 (es) Uso de los compuestos 2,5 dihidroxibencesulfonicos para la fabricacion de un medicamento para pacientes diabeticos
Van Wyk et al. In vitro antimicrobial activity of medicinal plants against oral Candida albicans isolates
RU2141816C1 (ru) Средство для лечения заболеваний пародонта и травматических повреждений слизистой оболочки полости рта &#34;виспосил&#34;
Thakur et al. Management of Ekakushta, with special reference to psoriasis, through Panchakarma: A case study
Obikeze Cardiovascular effects of Leonotis leonurus extracts in normotensive rats and in isolated perfused rat heart
Sloan This Month in JAAD Case Reports: December 2023–Topical cyclosporine for pyoderma gangrenosum

Legal Events

Date Code Title Description
FB Suspension of granting procedure